1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,426 | 0,515 | 12:01 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | RECBIO-B (02179): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 AND PROPOSED CHANGE OF THE USE OF PROCEEDS | 1 | HKEx | ||
| Di | RECBIO-B (02179): CHANGE OF JOINT COMPANY SECRETARIES, AUTHORISED REPRESENTATIVE AND PROCESS AGENT | 1 | HKEx | ||
| 12.03. | RECBIO-B (02179): DATE OF BOARD MEETING | - | HKEx | ||
| JIANGSU RECBIO TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 06.02. | RECBIO-B (02179): INSIDE INFORMATION ANNOUNCEMENT GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR THE H SHARE FULL CIRCULATION PLAN OF THE COMPANY | 1 | HKEx | ||
| 30.01. | RECBIO-B (02179): INSIDE INFORMATION ANNOUNCEMENT ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION PLAN OF THE COMPANY | 1 | HKEx | ||
| 29.12.25 | RECBIO-B (02179): VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF THE NEW DRUG APPLICATION FOR THE COMPANY'S NOVEL ADJUVANTED RECOMBINANT SHINGLES VACCINE REC610 ... | 2 | HKEx | ||
| 23.12.25 | RECBIO-B (02179): CHANGE OF THE CHAIRMAN OF THE BOARD OF DIRECTORS AND ADJUSTMENT TO THE COMPOSITION OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 19.12.25 | RECBIO-B (02179): RULES OF PROCEDURE FOR THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 19.12.25 | RECBIO-B (02179): RULES OF PROCEDURE FOR THE GENERAL MEETINGS | 1 | HKEx | ||
| 19.12.25 | RECBIO-B (02179): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 19.12.25 | RECBIO-B (02179): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 19.12.25 | RECBIO-B (02179): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 19, 2025; AMENDMENTS TO THE ARTICLES OF ASSOCIATION; ABOLISHMENT ... | 1 | HKEx | ||
| 17.12.25 | RECBIO-B (02179): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 17.12.25 | RECBIO-B (02179): ANNOUNCEMENT IN RELATION TO COMPLETION OF THE ISSUANCE OF DOMESTIC SHARES | 2 | HKEx | ||
| 01.12.25 | RECBIO-B (02179): FORM OF PROXY FOR USE AT THE 2025 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON FRIDAY, DECEMBER 19, 2025 | - | HKEx | ||
| 01.12.25 | RECBIO-B (02179): NOTICE OF EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 01.12.25 | RECBIO-B (02179): PROPOSED ABOLISHMENT OF THE SUPERVISORY BOARD AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ITS ATTACHMENTS; PROPOSED ELECTION OF ... | - | HKEx | ||
| 01.12.25 | RECBIO-B (02179): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD | 3 | HKEx | ||
| 01.12.25 | RECBIO-B (02179): TERMS OF REFERENCE OF THE REMUNERATION AND APPRAISAL COMMITTEE OF THE BOARD | - | HKEx | ||
| 01.12.25 | RECBIO-B (02179): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD | 1 | HKEx |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,615 | -4,95 % | Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment benefit compared to 15% and 22% reductions... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,210 | -4,98 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| EDITAS MEDICINE | 2,041 | +0,79 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,170 | -4,17 % | SRPT Stock Surges on Promising Early Results From siRNA Programs | ||
| BASILEA | 56,50 | -1,40 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea startet erste klinische Studie am Menschen für neuartiges Antibiotikum BAL2420 | Allschwil, 23. März 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 8,032 | +3,72 % | IBA SA: Telix selects IBA Cyclone KIUBE to support manufacturing expansion in the U.S. | Louvain-la-Neuve, Belgium- March 20, 2026 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical... ► Artikel lesen | |
| REPLIGEN | 95,46 | +0,72 % | Repligen Corporation: Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year... ► Artikel lesen | |
| UNIQURE | 13,500 | -1,46 % | uniQure Inc.: uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease | LEXINGTON, Mass. and AMSTERDAM, March 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs... ► Artikel lesen | |
| CODEXIS | 1,393 | +2,35 % | Analyst Sentiment Unchanged After Codexis (CDXS) Earnings | ||
| ORUKA THERAPEUTICS | 39,000 | -1,02 % | Piper Sandler bestätigt "Overweight"-Rating für Oruka Therapeutics | ||
| MACROGENICS | 2,750 | +0,81 % | MacroGenics, Inc.: MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures | Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026Lorigerlimab Phase 2 LINNET study update in mid-2026IND submission for MGC030... ► Artikel lesen | |
| OMEROS | 9,000 | +0,50 % | Omeros Corporation: Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment | Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22,... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,045 | -4,44 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update | Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero's... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 16,900 | +3,05 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update | $49.1 million global net product revenue of EKTERLY (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms received in the US from launch through end of February... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 3,160 | +1,94 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer | Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic
MORRISTOWN, N.J., Dec. 1, 2025 /PRNewswire/ -- Whitehawk... ► Artikel lesen |
JIANGSU RECBIO TECHNOLOGY CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,440 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JIANGSU RECBIO TECHNOLOGY CO LTD finden Sie auf Wallstreet Online.